Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:MDCX

Medicus Pharma 11/14/2025 Earnings Report

Medicus Pharma logo
$0.30 +0.01 (+4.90%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$0.30 +0.00 (+1.00%)
As of 05/22/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Medicus Pharma EPS Results

Actual EPS
-$0.65
Consensus EPS
-$0.38
Beat/Miss
Missed by -$0.27
One Year Ago EPS
N/A

Medicus Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Medicus Pharma Announcement Details

Quarter
Date
11/14/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Medicus Pharma's next earnings date is estimated for Monday, August 10, 2026, based on past reporting schedules.

Conference Call Resources

Medicus Pharma Earnings Headlines

Medicus Pharma Ltd. (MDCXW) Reports FDA Progress and Expands 2026 Clinical Outlook
May 19, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/medicus-pharma-ltd-mdcxw-reports-fda-progress-and-expands-2026-clinical-outlook-1764500/
Medicus Pharma sees catalyst-rich year ahead as SkinJect and Teverelix progress
May 15, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1092378?snapi
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
May 23 at 1:00 AM  |  Brownstone Research (Ad)
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3295423/0/en/medicus-pharma-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html
Exclusive: Medicus sees strongest efficacy at higher dose in skin cancer study
May 6, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/exclusive-medicus-sees-strongest-efficacy-at-higher-dose-in-skin-cancer-study/ar-AA22vqMm
Medicus Pharma reports strong Phase 2 dose response in skin cancer study
May 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/video/medicus-pharma-reports-strong-phase-161215536.html
See More Medicus Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicus Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicus Pharma and other key companies, straight to your email.

About Medicus Pharma

Medicus Pharma (NASDAQ:MDCX), Inc., traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies. Its research and development efforts are centered on expanding a pipeline that includes additional oncology supportive care candidates as well as treatments aimed at acute neurological and critical conditions. The company partners with established contract manufacturers and distributors to facilitate efficient production and market access.

Medicus Pharma primarily serves the U.S. market through a network of specialty pharmacies and hospital systems and is evaluating opportunities for international distribution. Led by a management team with experience in specialty pharmaceuticals, regulatory affairs and commercial operations, the company remains focused on advancing its pipeline and delivering targeted support therapies for patients undergoing cancer treatment and acute care interventions.

View Medicus Pharma Profile
Earnings Tools